GLP-1s Are Growing In Popularity As Weight Loss Drugs But Losing Steam Among Diabetics, Study Suggests

Semaglutide—the brand name for Ozempic and Wegovy—was the most prescribed GLP-1 in 2023, and accounted for over 88% of all new prescriptions.